SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Judy Garland

PatientJudy Garland
Date of birth1993-06-10
IdentifiersMRN HR-ML005-SYN; SSN (made up) 000-05-6127
Document date2026-06-29
AuthorMargaret Ellsworth-Diaz, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

One-week review, seen the same day by addiction medicine. [S]

History of Present Illness

Ms. Garland returns one week after intake and is seen by Dr. Grünewald of addiction medicine on the same day. She has taken secobarbital 200 mg at bedtime from the seven-day supply on six nights; on one night before a recording session she took a third capsule when she could not sleep, and she told us so herself. She has had no daytime shakes, sweats, or seizure-like episodes. She has taken dextroamphetamine 10 mg each morning and no extra doses, and she has felt flat and tired in the afternoons. She has taken sertraline 25 mg daily without nausea or headache. She brought 38 unused secobarbital capsules and 22 dextroamphetamine tablets from earlier prescriptions, which she placed in the pharmacy take-back box with the nurse today. She keeps this week's supply in a locked box. She has two weeks free of performances from next week and would like to use them for the change. [S]

ElementDetail
Secobarbital200 mg at bedtime on six nights; 300 mg on one night
Withdrawal symptomsNone
Dextroamphetamine10 mg each morning; no extra doses
Sertraline25 mg daily for a week; no side effects
Take-back38 secobarbital capsules and 22 dextroamphetamine tablets returned today
WorkTwo weeks without performances from next week

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired in the afternoons; no fever
NeurologicalNegativeNo tremor, unsteadiness or seizure-like episodes
PsychiatricPositiveLow mood and worry, a little better; no thoughts of suicide or self-harm

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicineTwo capsules at bedtime; no extra dosesOral route2026-06-22 to 2026-07-06completedS
Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energyOne tablet each morningOral route2026-06-22 to 2026-07-20completedS
Sertraline 25 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-06-22 to 2026-06-29completedS
Sertraline 50 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-06-29activeS
Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks150 mg intramuscularly every 13 weeksIntramuscular route2026-06-22activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-06-29Body height151cmS
2026-06-29Body weight46.8kgS
2026-06-29Body mass index (BMI) [Ratio]20.5kg/m2S
2026-06-29Systolic blood pressure124mm[Hg]S
2026-06-29Diastolic blood pressure80mm[Hg]S
2026-06-29Heart rate92/minS
2026-06-29Respiratory rate16/minS
2026-06-29Body temperature36.7CelS
2026-06-29Oxygen saturation in Arterial blood by Pulse oximetry99%S

Physical Exam

Vital signs recorded on 2026-06-29; see the Vital Signs section. [S]

SystemFinding
GeneralAlert; blood pressure 124/80, pulse 92
NeurologicalNo tremor; no nystagmus; gait steady
PsychiatricEngaged and candid; no signs of intoxication or withdrawal

Problems

ProblemClinical statusVerificationCodeProvenance
Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pillsactiveconfirmed F13.20S — Synthetic modern coding. Tolerance and withdrawal are not counted toward the diagnosis for a medicine taken under medical supervision; five other criteria are met. Person-first language; not a claim about her real diagnosis.
Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pillsactiveconfirmed F15.10S — Synthetic modern coding; DSM-5-TR mild stimulant use disorder maps to F15.10. Tolerance and withdrawal are not counted for a supervised prescription.
Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescenceactiveconfirmed G47.00S — Synthetic modern diagnosis anchored to the documented sleeping pills.
Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implantsactiveconfirmed Z30.013S — Synthetic contraception need; the birth is documented.
Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomaniaactiveconfirmed F32.1S — Synthetic modern diagnosis; not a claim about her real mood. The roster's bipolar disorder lead is not supported by the sources read and is not used.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyBarbiturate dose, adherence, extra doses, and withdrawal signs (tremor, sweating, pulse, sleep, seizure warning signs)Every visitCompleted today200 mg on six nights and 300 mg on one; no withdrawal signs
ReferralSetting for barbiturate withdrawalBefore any reductionOrderedFour-day admission to the addiction medicine service planned for next week, as advised today
Medication safetyPrescription drug monitoring program checkBefore every controlled-substance prescriptionCompleted todayOnly this clinic's prescriptions since intake
LaboratoryUrine drug testing, explained as part of careAt the start, after the change to phenobarbital, and periodically during the taperUp to dateAt intake: barbiturates and amphetamine only; no opioids, fentanyl or benzodiazepines
Medication safetyLimited dispensing, locked storage and take-back of unused capsulesSeven days at first, then two weeks at a timeCompleted todaySeven-day supply; locked box; 38 capsules and 22 tablets taken back today
Medication safetyStimulant dose, extra doses, cravings, and blood pressure and pulseEvery visitCompleted today10 mg each morning, no extra doses; blood pressure 124/80, pulse 92
SurveyCBT for insomnia, sleep diary and Insomnia Severity IndexWeekly CBT-I sessions; sleep diary and index at each visitCompleted todayFirst CBT-I session booked; sleep diary started; Insomnia Severity Index 21 (moderate)
Medication safetyNew hypnotic (benzodiazepine, Z-drug, trazodone or antihistamine)Not recommended as a replacementNot indicatedNo new hypnotic during the barbiturate taper
SurveyDepression (PHQ-9)At least monthly during acute treatmentUp to datePHQ-9 14 a week ago; next at the four-week visit
Medication safetySertraline adherence and side effectsTwo weeks after starting or changing the dose, then each visitCompleted todayNo side effects on 25 mg; increased to 50 mg
SurveySuicide-risk review (C-SSRS screen since the last visit), safety plan, means safety and the 988 Suicide & Crisis LifelineEvery visitCompleted todayC-SSRS screen negative since the last visit; unused capsules returned; the 988 Suicide & Crisis Lifeline in her phone
Self-managementPsychotherapyWeeklyCompleted todayFirst session this week
ExaminationWeight, meals and disordered-eating screen, without a weight targetEvery visitCompleted todayWeight 46.8 kg; eating one or two meals a day
Medication safetyNaloxoneReassess at every visit and whenever an opioid is prescribedNot indicatedNo opioids prescribed or used; naloxone would not reverse a barbiturate
ReferralAddiction medicine consultationAt the start of treatmentCompleted todaySeen by Dr. Grünewald today

Goal progress:

Guideline basis: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016); Prescription Drug Monitoring Programs (PDMPs) (2026); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Hospital admission in one week. Four-week review after discharge. Weekly psychotherapy and CBT-I. Next scheduled visit 2026-07-20: four-week review eleven days after a supervised hospital change from secobarbital to phenobarbital: starting the outpatient taper and the stimulant taper. [S]